Xintela AB: BioStock: Targinta positions itself in the ADC field
The Antibody-Drug Conjugates area has grown rapidly in recent years with several research advances, market approvals, and licensing agreements. A clear example is Pfizer's 43 billion USD acquisition of Seagen announced on March 13. Swedish Targinta, with its unique cancer target and First-in-Class antibodies, has developed a strong position in the ADC field.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se